Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
DURHAM, N.C., Feb. 22, 2016 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, February 29, 2016 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2015, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 51992168. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
